in the absence of a submission from the holder of the marketing authorisation:
trastuzumab deruxtecan (Enhertu®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice191KB (PDF)
Medicine details
- Medicine name:
- trastuzumab deruxtecan (Enhertu)
- SMC ID:
- SMC2888
- Indication:
Monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 December 2025